PUNE, India, October 1, 2015 /PRNewswire/ --
Fibromyalgia - Pipeline Review, H2 2015 is a new market research report that provides comprehensive information on the therapeutic development for Fibromyalgia, also known as fibromyalgia syndrome and fibrositis.
Complete report on fibromyalgia market pipeline for H2 2015 spread across 66 pages, talking about 6 companies, 10 drug profiles and supported with 25 tables and 14 figures is now available at http://www.reportsnreports.com/reports/426505-fibromyalgia-pipeline-review-h2-2015.html .
The Fibromyalgia - Pipeline Review, H2 2015 market research provides an overview of the Fibromyalgia's therapeutic pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
This fibromyalgia market pipeline review research for H2 2015 provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage and develop strategic initiatives by understanding the focus areas of leading companies. The report also helps identify and understand important and diverse types of therapeutics under development for Fibromyalgia, plan mergers and acquisitions effectively by identifying key players of the most promising pipeline and devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics. The fibromyalgia pipeline review report for H2 2015 also facilitates to develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope and modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies involved in fibromyalgia therapeutics development and covered in this pipeline review report are Daiichi Sankyo Company Limited, Intellipharmaceutics International Inc., Merck & Co. Inc., SWITCH Biotech LLC, Tonix Pharmaceuticals Holding Corp. and Zynerba Pharmaceuticals Inc. Drug profiles discussed in this research include mirogabalin besylate, mirtazapine ODT, naltrexone hydrochloride, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia, pregabalin XR, Small Molecules for Fibromyalgia, SWT-06101, TD-9855, TNX-102 and ZYN-001. Order a copy of Fibromyalgia - Pipeline Review, H2 2015 market research report at http://www.reportsnreports.com/Purchase.aspx?name=426505 .
The second research titled EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023 says in 2013, there were 23,663,533 total prevalent cases of fibromyalgia in the 7MM. Epidemiologists forecast that the total prevalent cases in the 7MM will increase to 24,881,838 by 2023, at an Annual Growth Rate (AGR) of 0.51%. All markets, except for Germany and Japan, will see a small increase in the number of cases at varying AGRs. Since epidemiologists held the prevalence constant throughout the forecast period, the differences observed in the total prevalent cases of fibromyalgia in the 7MM are driven by changes in the underlying population dynamics of each market. In the 7MM, fibromyalgia epidemiological studies have shown that women have a higher total prevalence of fibromyalgia compared with men. When the 1990 ACR criteria were used to define fibromyalgia, a majority of patients with fibromyalgia were women due to the greater number of female body tender points. However, the 2010 ACR criteria are entirely symptom-based, do not require tender point counts, and provide a more accurate sex distribution of total prevalent cases of fibromyalgia (Wolfe et al., 2011). Additional studies are needed to clarify the etiology of the association between sex and fibromyalgia. Complete report is available at http://www.reportsnreports.com/reports/401540-epicast-report-fibromyalgia-epidemiology-forecast-to-2023.html .
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts